The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity
ConditionOsteoporosis
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age40+
SponsorAarhus University Hospital
About this trial
Randomized, placebo controlled prospective trial evaluating the effect of denosumab on insulin sensitivity and muscle strength.
Eligibility criteria
Qualifiers
Postmenopausal women (postmenopausal for at least two years)
Age ≥ 40 years
BMD T-score ≥ -2.0 (lumbar spine, total hip or femoral neck)
At least 2 lumbar vertebrae that can be evaluated by dual-energy x-ray absorptiometry (DXA)
Disqualifiers
Treatment for osteoporosis at any time
Other antidiabetic medication than metformin
Low-energy vertebral fractures at any time
Low-energy hip fracture at any time
Trial design
Treatments tested in this trial
- Denosumab
- Saline (0.9% NaCl)
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Aarhus University Hospital
Lead sponsor
Sponsor: MD, Professor, DMSc, PhD Bente Lomholt Langdahl
Collaborator
Source ClinicalTrials.gov